子宮頸がんの診断検査:医療機器パイプライン分析

◆英語タイトル:Cervical Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2019
◆商品コード:GDT20FB0146
◆発行会社(リサーチ会社):GlobalData
◆発行日:2019年11月
◆ページ数:113
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD5,000 ⇒換算¥540,000見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD7,500 ⇒換算¥810,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Cervical Cancer Diagnostic Tests – Medical Devices Pipeline Assessment, 2019
Summary

GlobalData’s Medical Devices sector report, “Cervical Cancer Diagnostic Tests – Medical Devices Pipeline Assessment, 2019″ provides an overview of Cervical Cancer Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Cervical Cancer Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData’s team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Cervical Cancer Diagnostic Tests under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Cervical Cancer Diagnostic Tests and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to –
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Cervical Cancer Diagnostic Tests under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date

【レポートの目次】

Table of Contents
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Cervical Cancer Diagnostic Tests Overview 7
3 Products under Development 8
3.1 Cervical Cancer Diagnostic Tests – Pipeline Products by Stage of Development 8
3.2 Cervical Cancer Diagnostic Tests – Pipeline Products by Territory 9
3.3 Cervical Cancer Diagnostic Tests – Pipeline Products by Regulatory Path 10
3.4 Cervical Cancer Diagnostic Tests – Pipeline Products by Estimated Approval Date 11
3.5 Cervical Cancer Diagnostic Tests – Ongoing Clinical Trials 12
4 Cervical Cancer Diagnostic Tests – Pipeline Products under Development by Companies 13
4.1 Cervical Cancer Diagnostic Tests Companies – Pipeline Products by Stage of Development 13
4.2 Cervical Cancer Diagnostic Tests – Pipeline Products by Stage of Development 14
5 Cervical Cancer Diagnostic Tests Companies and Product Overview 15
5.1 Alere Inc Company Overview 15
5.1.1 Alere Inc Pipeline Products & Ongoing Clinical Trials Overview 15
5.2 Augusta University Company Overview 16
5.2.1 Augusta University Pipeline Products & Ongoing Clinical Trials Overview 16
5.3 Becton Dickinson and Co Company Overview 17
5.3.1 Becton Dickinson and Co Pipeline Products & Ongoing Clinical Trials Overview 17
5.4 Bio Techne Corp Company Overview 21
5.4.1 Bio Techne Corp Pipeline Products & Ongoing Clinical Trials Overview 21
5.5 BioAffinity Technologies, Inc. Company Overview 22
5.5.1 BioAffinity Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 22
5.6 BioMark Diagnostics Inc Company Overview 23
5.6.1 BioMark Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 23
5.7 BioMark Technologies Inc Company Overview 24
5.7.1 BioMark Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 24
5.8 Cepheid Company Overview 25
5.8.1 Cepheid Pipeline Products & Ongoing Clinical Trials Overview 25
5.9 China Sky One Medical Inc Company Overview 26
5.9.1 China Sky One Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 26
5.10 Cytosystems Ltd Company Overview 27
5.10.1 Cytosystems Ltd Pipeline Products & Ongoing Clinical Trials Overview 27
5.11 Enzo Biochem Inc Company Overview 28
5.11.1 Enzo Biochem Inc Pipeline Products & Ongoing Clinical Trials Overview 28
5.12 Exact Sciences Corp Company Overview 29
5.12.1 Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview 29
5.13 GenomicTree Inc Company Overview 30
5.13.1 GenomicTree Inc Pipeline Products & Ongoing Clinical Trials Overview 30
5.14 GRANT Life Sciences, Inc. Company Overview 32
5.14.1 GRANT Life Sciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview 32
5.15 HLL Lifecare Ltd Company Overview 33
5.15.1 HLL Lifecare Ltd Pipeline Products & Ongoing Clinical Trials Overview 33
5.16 Louisville Bioscience, Inc. Company Overview 34
5.16.1 Louisville Bioscience, Inc. Pipeline Products & Ongoing Clinical Trials Overview 34
5.17 MDNA Life Sciences Inc Company Overview 35
5.17.1 MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 35
5.18 MDxHealth SA Company Overview 36
5.18.1 MDxHealth SA Pipeline Products & Ongoing Clinical Trials Overview 36
5.19 Milagen Inc Company Overview 37
5.19.1 Milagen Inc Pipeline Products & Ongoing Clinical Trials Overview 37
5.20 Olympia Diagnostics Inc Company Overview 38
5.20.1 Olympia Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 38
5.21 Oncgnostics GmbH Company Overview 40
5.21.1 Oncgnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview 40
5.22 ONCOVEDA Cancer Research Center Company Overview 41
5.22.1 ONCOVEDA Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 41
5.23 Precision Biologics Inc Company Overview 42
5.23.1 Precision Biologics Inc Pipeline Products & Ongoing Clinical Trials Overview 42
5.24 US Biomarkers Inc Company Overview 43
5.24.1 US Biomarkers Inc Pipeline Products & Ongoing Clinical Trials Overview 43
5.25 XEPTAGEN SpA Company Overview 44
5.25.1 XEPTAGEN SpA Pipeline Products & Ongoing Clinical Trials Overview 44
6 Cervical Cancer Diagnostic Tests – Recent Developments 45
6.1 Nov 05, 2019: BD announces results for 2019 fourth fiscal quarter and full year; provides fiscal 2020 guidance 45
6.2 Oct 30, 2019: Genomic Vision: Financial information for the third quarter of 2019 46
6.3 Oct 23, 2019: AdvaMed Statement on BD Sterilization Plant in Georgia 47
6.4 Oct 22, 2019: Quest Diagnostics reports third quarter 2019 financial results 48
6.5 Oct 03, 2019: Genomic Vision and PolyAn sign an agreement for the production and supply of Coverslips 48
6.6 Sep 26, 2019: BD announces leadership succession plan 49
6.7 Sep 24, 2019: Genomic Vision: First-half 2019 results 50
6.8 Sep 10, 2019: Quest Diagnostics names Manuel O. Méndez as new commercial leader 53
6.9 Aug 29, 2019: MDxHealth reports half year 2019 financial results and strategic update 54
6.10 Aug 26, 2019: New technique isolates placental cells for non-invasive genetic testing 56
6.11 Aug 20, 2019: Cancer Genetics reports second quarter 2019 financial results and provides strategic business update 57
6.12 Aug 06, 2019: BD announces results for 2019 third fiscal quarter; reaffirms fiscal 2019 guidance 58
7 Appendix 110
7.1 Methodology 110
7.2 About GlobalData 113
7.3 Contact Us 113
7.4 Disclaimer 113

List of Tables
Table 1: Cervical Cancer Diagnostic Tests - Pipeline Products by Stage of Development 10
Table 2: Cervical Cancer Diagnostic Tests - Pipeline Products by Territory 11
Table 3: Cervical Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 12
Table 4: Cervical Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 13
Table 5: Cervical Cancer Diagnostic Tests - Ongoing Clinical Trials 14
Table 6: Cervical Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development 15
Table 7: Cervical Cancer Diagnostic Tests - Pipeline Products by Stage of Development 16
Table 8: Alere Inc Pipeline Products & Ongoing Clinical Trials Overview 17
Table 9: NMP179 Test - Product Status 17
Table 10: NMP179 Test - Product Description 17
Table 11: Augusta University Pipeline Products & Ongoing Clinical Trials Overview 18
Table 12: Folate Receptor Biomarker Test - Cervical Cancer Diagnostic Tests - Product Status 18
Table 13: Folate Receptor Biomarker Test - Cervical Cancer Diagnostic Tests - Product Description 18
Table 14: Becton Dickinson and Co Pipeline Products & Ongoing Clinical Trials Overview 19
Table 15: BD SurePath Plus Molecular Pap Test System - Product Status 19
Table 16: BD SurePath Plus Molecular Pap Test System - Product Description 19
Table 17: Biomarker Test - Cervical Cancer Diagnostic Tests - Product Status 20
Table 18: Biomarker Test - Cervical Cancer Diagnostic Tests - Product Description 20
Table 19: Becton Dickinson and Co - Ongoing Clinical Trials Overview 21
Table 20: BD SurePath Plus Molecular Pap Test System - Validation of High Resolution Microendoscope in the Screening of Cervical Cancer Precursor Lesions in Brazil: UH3 - Brazil 22
Table 21: Bio Techne Corp Pipeline Products & Ongoing Clinical Trials Overview 23
Table 22: RNAscope HPV Assay - Cervical Cancer Diagnostic Tests - Product Status 23
Table 23: RNAscope HPV Assay - Cervical Cancer Diagnostic Tests - Product Description 23
Table 24: BioAffinity Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 25
Table 25: CyPath Diagnostic Assay - Cervical Cancer Diagnostic Tests - Product Status 25
Table 26: CyPath Diagnostic Assay - Cervical Cancer Diagnostic Tests - Product Description 25
Table 27: BioMark Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 26
Table 28: Metabolomics-based Diagnostic Assay - Cervical Cancer Diagnostic Tests - Product Status 26
Table 29: Metabolomics-based Diagnostic Assay - Cervical Cancer Diagnostic Tests - Product Description 26
Table 30: BioMark Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 28
Table 31: Biomarker Assay - Cervical Cancer Diagnostic Tests - Product Status 28
Table 32: Biomarker Assay - Cervical Cancer Diagnostic Tests - Product Description 28
Table 33: Cepheid Pipeline Products & Ongoing Clinical Trials Overview 29
Table 34: Xpert Molecular PAP Assay - Product Status 29
Table 35: Xpert Molecular PAP Assay - Product Description 29
Table 36: China Sky One Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 30
Table 37: Diagnostic Kit - Carcinoma Cervix - Product Status 30
Table 38: Diagnostic Kit - Carcinoma Cervix - Product Description 30
Table 39: Cytosystems Ltd Pipeline Products & Ongoing Clinical Trials Overview 31
Table 40: Laboratory-Based Diagnostic Test - Cervical Cancer Diagnostic Tests - Product Status 31
Table 41: Laboratory-Based Diagnostic Test - Cervical Cancer Diagnostic Tests - Product Description 31
Table 42: Enzo Biochem Inc Pipeline Products & Ongoing Clinical Trials Overview 32
Table 43: p16 Biomarker - Cervical Cancer Diagnostic Tests - Product Status 32
Table 44: p16 Biomarker - Cervical Cancer Diagnostic Tests - Product Description 32
Table 45: Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview 33
Table 46: Liquid Biopsy Test - Cervical Cancer Diagnostic Tests - Product Status 33
Table 47: Liquid Biopsy Test - Cervical Cancer Diagnostic Tests - Product Description 33
Table 48: GenomicTree Inc Pipeline Products & Ongoing Clinical Trials Overview 35
Table 49: EarlyTect Cervical Cancer Diagnostic Tests - Product Status 35
Table 50: EarlyTect Cervical Cancer Diagnostic Tests - Product Description 35
Table 51: Screening Test - Cervical Cancer Diagnostic Tests - Product Status 36
Table 52: Screening Test - Cervical Cancer Diagnostic Tests - Product Description 36
Table 53: GRANT Life Sciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview 37
Table 54: Serum-Based Test - Cervical Cancer Diagnostic Tests - Product Status 37
Table 55: Serum-Based Test - Cervical Cancer Diagnostic Tests - Product Description 37
Table 56: HLL Lifecare Ltd Pipeline Products & Ongoing Clinical Trials Overview 38
Table 57: Diagnostic ELISA - Cervical Cancer Diagnostic Tests - Product Status 38
Table 58: Diagnostic ELISA - Cervical Cancer Diagnostic Tests - Product Description 38
Table 59: Louisville Bioscience, Inc. Pipeline Products & Ongoing Clinical Trials Overview 39
Table 60: Cervical Cancer Remission pT Test - Product Status 39

List of Figures
Figure 1: Cervical Cancer Diagnostic Tests - Pipeline Products by Stage of Development 8
Figure 2: Cervical Cancer Diagnostic Tests - Pipeline Products by Territory 9
Figure 3: Cervical Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 10
Figure 4: Cervical Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 11
Figure 5: Cervical Cancer Diagnostic Tests - Ongoing Clinical Trials 12

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[子宮頸がんの診断検査:医療機器パイプライン分析]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆